United Therapeutics Shares Outstanding 2006-2019 | UTHR

United Therapeutics shares outstanding from 2006 to 2019. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
United Therapeutics Annual Shares Outstanding
(Millions of Shares)
2018 44
2017 45
2016 47
2015 51
2014 54
2013 53
2012 53
2011 59
2010 60
2009 56
2008 46
2007 45
2006 48
2005 50
United Therapeutics Quarterly Shares Outstanding
(Millions of Shares)
Q3 2019 44
Q2 2019 44
Q1 2019 44
Q4 2018 44
Q3 2018 44
Q2 2018 43
Q1 2018 44
Q4 2017 45
Q3 2017 44
Q2 2017 45
Q1 2017 46
Q4 2016 47
Q3 2016 46
Q2 2016 47
Q1 2016 49
Q4 2015 51
Q3 2015 50
Q2 2015 52
Q1 2015 47
Q4 2014 54
Q3 2014 47
Q2 2014 53
Q1 2014 57
Q4 2013 53
Q3 2013 54
Q2 2013 53
Q1 2013 52
Q4 2012 53
Q3 2012 54
Q2 2012 54
Q1 2012 55
Q4 2011 59
Q3 2011 61
Q2 2011 63
Q1 2011 63
Q4 2010 60
Q3 2010 60
Q2 2010 60
Q1 2010 60
Q4 2009 56
Q3 2009 58
Q2 2009 53
Q1 2009 54
Q4 2008 46
Q3 2008 51
Q2 2008 49
Q1 2008 48
Q4 2007 45
Q3 2007 45
Q2 2007 44
Q1 2007 43
Q4 2006 48
Q3 2006 50
Q2 2006 51
Q1 2006 51
Q4 2005 50
Q3 2005 51
Q2 2005 50
Q1 2005 49
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $4.572B $1.628B
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening conditions. United Therapeutics (UT) has an overarching commitment to environmental sustainability. The company's product candidates include Adcirca is a phosphodiesterase 5 (PDE-5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH)(WHO Group 1) to improve exercise ability in PAH patients. Orenitram is a prostacyclin vasodilator indicated for treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise capacity. Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise. Tyvaso is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $68.471B 39.61
Takeda Pharmaceutical (TAK) Japan $60.597B 10.74
Astellas Pharma (ALPMY) Japan $32.582B 16.27
Eisai (ESALY) Japan $23.185B 44.70
Merck (MKGAF) Germany $17.215B 23.49
Grifols, S.A (GRFS) Spain $16.941B 22.20
Neurocrine Biosciences (NBIX) United States $9.626B 267.44
Ono Pharmaceutical (OPHLF) Japan $9.450B 20.20
Catalent (CTLT) United States $8.851B 36.42
Ionis Pharmaceuticals (IONS) United States $8.458B 17.13
Recordati Industria Chimica E Farmaceutica S.P.A (RCDTF) Italy $8.449B 0.00
Jazz Pharmaceuticals (JAZZ) Ireland $7.968B 10.18
IPSEN SA ADR (IPSEY) France $6.104B 0.00
Orion OYJ (ORINY) Finland $5.871B 0.00
STADA ARZNEIMI (STDAF) Germany $5.543B 0.00
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $5.540B 0.00
Hypermarcas (HYPMY) Brazil $5.461B 16.61
Evotec AG (EVTCY) Germany $4.261B 68.88
Arrowhead Pharmaceuticals (ARWR) United States $4.195B 77.87
Nektar Therapeutics (NKTR) United States $4.069B 0.00
FibroGen (FGEN) United States $3.977B 116.87
PTC Therapeutics (PTCT) United States $3.559B 0.00
Sage Therapeutics (SAGE) United States $3.528B 0.00
Taro Pharmaceutical Industries (TARO) Israel $2.790B 11.29
ChemoCentryx (CCXI) United States $2.786B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $2.092B 0.00
Pacira Pharmaceuticals (PCRX) United States $2.086B 61.72
Xencor (XNCR) United States $2.070B 62.91
Ironwood Pharmaceuticals (IRWD) United States $1.891B 23.19
Heron Therapeutics (HRTX) United States $1.891B 0.00
Tilray (TLRY) Canada $1.748B 0.00
USANA Health Sciences (USNA) United States $1.626B 17.00
Corcept Therapeutics (CORT) United States $1.525B 18.53
CLINIGEN GP (CLIGF) United Kingdom $1.506B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $1.469B 10.02
Zogenix (ZGNX) United States $1.424B 0.00
Theravance Biopharma (TBPH) Cayman Islands $1.424B 0.00
Endo (ENDP) Ireland $1.395B 2.56
Portola Pharmaceuticals (PTLA) United States $1.062B 0.00
Akebia Therapeutics (AKBA) United States $1.041B 0.00
Enanta Pharmaceuticals (ENTA) United States $1.034B 32.03
Dermira (DERM) United States $1.022B 0.00
ImmunoGen (IMGN) United States $1.018B 0.00
Karyopharm Therapeutics (KPTI) United States $0.966B 0.00
Radius Health (RDUS) United States $0.922B 0.00
Aerie Pharmaceuticals (AERI) United States $0.901B 0.00
Collegium Pharmaceutical (COLL) United States $0.775B 0.00
TherapeuticsMD (TXMD) United States $0.673B 0.00
Flexion Therapeutics (FLXN) United States $0.631B 0.00
Crinetics Pharmaceuticals (CRNX) United States $0.543B 0.00
Molecular Templates (MTEM) United States $0.536B 0.00
Catalyst Pharmaceuticals (CPRX) United States $0.492B 59.63
BioSpecifics Technologies Corp (BSTC) United States $0.478B 20.59
Ardelyx (ARDX) United States $0.474B 0.00
Translate Bio (TBIO) United States $0.471B 0.00
Aptorum Group (APM) Hong Kong, SAR China $0.444B 0.00
Innate Pharma SA (IPHYF) France $0.442B 0.00
Organogenesis Holdings (ORGO) United States $0.431B 0.00
Recro Pharma (REPH) United States $0.420B 0.00
Indivior (INVVY) United States $0.417B 2.48
BioCryst Pharmaceuticals (BCRX) United States $0.415B 0.00
Siga Technologies (SIGA) United States $0.393B 8.98
DURECT (DRRX) United States $0.377B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.372B 0.00
Harpoon Therapeutics (HARP) United States $0.370B 0.00
Lannett Co Inc (LCI) United States $0.367B 5.91
Calithera Biosciences (CALA) United States $0.366B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.356B 0.00
Rafael Holdings (RFL) United States $0.349B 0.00
Concert Pharmaceuticals (CNCE) United States $0.322B 0.00
Spectrum Pharmaceuticals (SPPI) United States $0.320B 0.00
OptiNose (OPTN) United States $0.285B 0.00
Foamix Pharmaceuticals (FOMX) Israel $0.272B 0.00
KalVista Pharmaceuticals (KALV) United States $0.270B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $0.267B 0.00
Ocular Therapeutix (OCUL) United States $0.250B 0.00
La Jolla Pharmaceutical (LJPC) United States $0.228B 0.00
MEI Pharma (MEIP) United States $0.227B 0.00
IMV INC (IMV) Canada $0.213B 0.00
Oasmia Pharmaceutical AB (OASMY) Sweden $0.205B 0.00
Nature's Sunshine Products (NATR) United States $0.205B 35.27
Taiwan Liposome (TLC) Taiwan $0.200B 0.00
Jounce Therapeutics (JNCE) United States $0.194B 2.60
AcelRx Pharmaceuticals (ACRX) United States $0.127B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.125B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.124B 0.00
CannTrust Holdings (CTST) Canada $0.119B 0.00
Otonomy (OTIC) United States $0.114B 0.00
Aquestive Therapeutics (AQST) United States $0.110B 0.00
Redhill Biopharma (RDHL) Israel $0.110B 0.00
ASSERTIO THERAPEUTICS, INC (ASRT) United States $0.108B 0.00
Xeris Pharmaceuticals (XERS) United States $0.108B 0.00
ALLERGY THERAPT (AGYTF) United Kingdom $0.097B 0.00
CV Sciences (CVSI) United States $0.094B 0.00
Champions Oncology (CSBR) United States $0.084B 0.00
MediWound (MDWD) Israel $0.081B 0.00
Neos Therapeutics (NEOS) United States $0.078B 0.00
Infinity Pharmaceuticals (INFI) United States $0.078B 0.00
Onconova Therapeutics (ONTX) United States $0.074B 0.00
CTI BioPharma (CTIC) United States $0.072B 0.00
Entasis Therapeutics Holdings (ETTX) United States $0.070B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.068B 20.23
RENEURON GP (RNUGF) United Kingdom $0.059B 0.00
SCYNEXIS (SCYX) United States $0.057B 0.00
Aclaris Therapeutics (ACRS) United States $0.056B 0.00
Nivalis Therapeutics (ALPN) United States $0.056B 0.00
Opiant Pharmaceuticals (OPNT) United States $0.053B 0.00
VAXART, INC (VXRT) United States $0.052B 0.00
Bellicum Pharmaceuticals (BLCM) United States $0.052B 0.00
Natural Alternatives (NAII) United States $0.052B 23.44
Dipexium Pharmaceuticals (PLXP) United States $0.047B 0.00
Summit Therapeutics (SMMT) United Kingdom $0.047B 0.00
PolarityTE (PTE) United States $0.046B 0.00
Adamis Pharmaceuticals (ADMP) United States $0.045B 0.00
Forward Pharma (FWP) Denmark $0.043B 0.00
Mannatechorporated (MTEX) United States $0.038B 0.00
Iterum Therapeutics (ITRM) Ireland $0.037B 0.00
Jaguar Animal Health (JAGX) United States $0.035B 0.00
ElectroCore (ECOR) United States $0.031B 0.00
Biomerica (BMRA) United States $0.028B 0.00
PharmAthene (ALT) United States $0.027B 0.00
Eyegate Pharmaceuticals (EYEG) United States $0.027B 0.00
China SXT Pharmaceuticals (SXTC) China $0.024B 0.00
ProPhase Labs (PRPH) United States $0.021B 0.00
Bio-Path Holdings (BPTH) United States $0.019B 0.00
Regulus Therapeutics (RGLS) United States $0.018B 0.00
Cardiome Pharma (CORV) Canada $0.017B 0.00
Shineco (TYHT) China $0.015B 0.00
Kitov Pharmaceuticals Holdings (KTOV) Israel $0.015B 0.00
Heat Biologics (HTBX) United States $0.014B 0.00
HANCOCK JAFFE (HJLI) United States $0.013B 0.00
Novan (NOVN) United States $0.013B 0.00
Cyanotech (CYAN) United States $0.013B 0.00
Lipocine (LPCN) United States $0.012B 0.00
Vical (BBI) United States $0.010B 0.00
Cytori Therapeutics Inc (PSTV) United States $0.008B 0.00
Tetraphase Pharmaceuticals (TTPH) United States $0.008B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.007B 0.00
Xenetic Biosciences (XBIO) United States $0.005B 0.00
Flex Pharma (SLRX) United States $0.004B 0.00
RXi Pharmaceuticals (PHIO) United States $0.002B 0.00
Midatech Pharma (MTP) United Kingdom $0.002B 0.00